Clinical data supporting the dysregulationof GRN, PAI-1, IL-6, IL-6R, and GRN in patients of COVID-19 emphasizethe potential role of these binding interactions in disease severitywhile also highlighting a niche therapeutic strategy toward managingsevere infections.18,22,22 Thus, our results that FANA-760 and FANA-34 can act as competitiveinhibitors of the respective miRs binding to SARS-CoV-2 3′-UTRhighlight their potential as therapeutic agents. This evidence concerns the gene IL6 and infection.